Jefferies Downgrades Ampio Pharmaceuticals (AMPE) to Hold
Get Alerts AMPE Hot Sheet
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Jefferies downgraded Ampio Pharmaceuticals (NYSE: AMPE) from Buy to Hold with a price target of $5.00 (from $14.00).
Analyst Biren Amin said, "We are downgrading AMPE shares to a Hold from a Buy on a lack of confidence in the direction of the Ampion program. The company announced that the PIII STEP trial observed a significant setback when 73% of Ampion clinical supply in STEP may have been exposed to temperatures below 15 degrees Celsius. AMPE expects to disclose full efficacy data upon discussing w/ the FDA, which is anticipated in 3-4 weeks."
The cut FY 2014 EPS from ($0.70) to ($0.75) and FY 2015 EPS from ($0.58) to ($0.69).
For an analyst ratings summary and ratings history on Ampio Pharmaceuticals click here. For more ratings news on Ampio Pharmaceuticals click here.
Shares of Ampio Pharmaceuticals closed at $5.66 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AO World Plc. (AO/:LN) PT Raised to GBP1.25 at Jefferies
- Safran SA (SAF:FP) (SAFRY) PT Raised to EUR211 at Citi, 'remain positive on the aftermarket'
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT Change, DowngradesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!